CNS Delivery of Immunotherapy Using MSCs

About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
A2006027
Acknowledgement
Summary
The focus of this proposal is on immunotherapy (vaccine) as an experimental approach to treat Alzheimer’s disease. Dr. Cribbs plans to directly delivery specific antibodies to the central nervous system to attack the toxic amyloid peptide that accumulates in the brain. The antibodies will be delivered by the patient’s own stem cells which will be isolated from their bone marrow. These stem cells will be genetically modified to make the antibodies, and then they will be injected into the brain where they will go to the sites of brain inflammation and secrete the therapeutic antibodies.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD